Literature DB >> 2789191

Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes.

M Haak-Frendscho1, K M Young, C J Czuprynski.   

Abstract

The effects of exogenously administered human recombinant IL-2 (hrIL-2) on resistance to Listeria monocytogenes infection were examined. Intravenous injection of hrIL-2 significantly enhanced antibacterial resistance in both BDF1 and C3H/HeJ mice. The beneficial effect of hrIL-2 was observed with as little as 0.6 micrograms per mouse, whereas optimum protection occurred at 6 micrograms per mouse, hrIL-2 was equally protective when administered concomitant with the listeriae or up to 24 h prior to infection; it had little effect if given after the bacterial challenge. Kinetic experiments indicated that both the peak bacterial burden and the time lag before L. monocytogenes began to be cleared from the spleen and liver were reduced in hrIL-2-treated mice as compared with control mice. Histopathological examination of spleens and livers confirmed that hrIL-2-treated Listeria-infected mice experienced considerably less damage to these organs than did control mice. Spleen cells from Listeria-infected mice exhibited depressed levels of mitogen-induced proliferation coincident with the peak bacterial burden in the spleen and liver and during the subsequent recovery from the infection. Administration of hrIL-2 to uninfected mice had no effect on spleen cell proliferation in response to mitogens in vitro, nor did hrIL-2 treatment restore normal levels of splenocyte proliferative responses to Listeria-infected mice. In addition, hrIL-2 treatment resulted in attenuated levels of serum colony-stimulating activity in infected mice as compared with control infected mice. Coadministration of both hrIL-2 and human recombinant interleukin-1 alpha at various dose and time combinations had no detectable additive or synergistic effect. Although these data do not suggest an obvious mechanism of action, they clearly demonstrate that hrIL-2 can augment host defense against the facultative intracellular pathogen L. monocytogenes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789191      PMCID: PMC260764          DOI: 10.1128/iai.57.10.3014-3021.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection.

Authors:  C J Czuprynski; J F Brown; K M Young; A J Cooley; R S Kurtz
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

2.  T-cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: superior role of Lyt-2+ cells in acquired immunity.

Authors:  M E Mielke; S Ehlers; H Hahn
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

3.  Dual regulation of anti-bacterial resistance and inflammatory neutrophil and macrophage accumulation by L3T4+ and Lyt 2+ Listeria-immune T cells.

Authors:  C J Czuprynski; J F Brown
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.

Authors:  G Weil-Hillman; J A Hank; N S Rosenthal; P M Sondel
Journal:  J Biol Response Mod       Date:  1988-10

5.  Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria.

Authors:  K T Chong
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

6.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

7.  Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice.

Authors:  A Jeevan; G L Asherson
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

8.  Lysis of murine macrophages infected with intracellular pathogens by interleukin 2-activated killer (LAK) cells in vitro.

Authors:  M Resnick; N Roguel; H Bercovier; C Enk; S Frankenburg; E Kedar
Journal:  Cell Immunol       Date:  1988-04-15       Impact factor: 4.868

9.  Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.

Authors:  M K Gately; T D Anderson; T J Hayes
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

10.  Cloned Listeria monocytogenes specific non-MHC-restricted Lyt-2+ T cells with cytolytic and protective activity.

Authors:  S H Kaufmann; H R Rodewald; E Hug; G De Libero
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

View more
  13 in total

Review 1.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Role of tumor necrosis factor in Listeria resistance of nude mice.

Authors:  T Hauser; K Frei; R M Zinkernagel; T P Leist
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

3.  Dynamics of avian inflammatory response to Salmonella-immune lymphokines. Changes in avian blood leukocyte populations.

Authors:  M H Kogut; E D McGruder; B M Hargis; D E Corrier; J R DeLoach
Journal:  Inflammation       Date:  1994-08       Impact factor: 4.092

4.  Use of recombinant interleukin-2 to enhance adoptive transfer of resistance to Listeria monocytogenes infection.

Authors:  M Haak-Frendscho; C J Czuprynski
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

5.  Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin.

Authors:  M Haak-Frendscho; S A Marsters; S M Chamow; D H Peers; N J Simpson; A Ashkenazi
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

6.  A membrane vesicle/ribosome preparation from Serratia marcescens elicits peritoneal exudate cells expressing both tumoricidal and bactericidal activity.

Authors:  C McCall; L Weimer; S Baldwin; D W Riches; B Canono; P A Campbell
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

7.  Analysis of cytokine mRNA expression in Listeria-resistant C57BL/6 and Listeria-susceptible A/J mice during Listeria monocytogenes infection.

Authors:  Y Iizawa; R D Wagner; C J Czuprynski
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Recombinant interleukin-6 protects mice against experimental bacterial infection.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria.

Authors:  M Denis
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

10.  Role of interleukin-6 in T-cell activation during primary and secondary infection with Listeria monocytogenes.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.